<DOC>
	<DOCNO>NCT03087968</DOCNO>
	<brief_summary>This clinical investigation substudy within GS-US-416-2124 , IND 129570 , A Phase 2 , Double-Blind , Randomized Study Evaluating Safety , Tolerability , Efficacy GS-4997 Combination Prednisolone versus Prednisolone Alone Subjects Severe Alcoholic Hepatitis . The use HepQuant SHUNT test ass liver disease severity , , treatment GS-4997 placebo , ass liver disease severity .</brief_summary>
	<brief_title>Evaluation HepQuant SHUNT Assess Liver Disease ; Substudy Within GS-US-416-2124</brief_title>
	<detailed_description>The main study Phase 2 , double blind , proof-of-concept , randomize study evaluate safety , tolerability , biological activity GS-4997 combination prednisolone , compare prednisolone alone , subject severe , histologically-confirmed AH . This substudy use HepQuant SHUNT Liver Diagnostic test ass severity disease baseline track disease progression improvement 24 week study . The HepQuant SHUNT test perform baseline ( Day 1 ) Weeks 1 , 2 , 4 , 12 , 24 regardless treatment Arm . GS-4997 Dose Mode Administration . Subjects randomize 1:1 either : - Treatment Group A : GS-4997 18 mg ( 1 x 18 mg tablet ) AND prednisolone 40 mg ( 4 x 10 mg tablet ) , administer orally daily - Treatment Group B : GS-4997 placebo ( 1 tablet ) AND prednisolone 40 mg ( 4 x 10 mg tablet ) , administer orally daily</detailed_description>
	<mesh_term>Liver Diseases</mesh_term>
	<mesh_term>Hepatitis , Alcoholic</mesh_term>
	<mesh_term>Prednisolone acetate</mesh_term>
	<mesh_term>Methylprednisolone acetate</mesh_term>
	<mesh_term>Prednisolone</mesh_term>
	<mesh_term>Methylprednisolone</mesh_term>
	<mesh_term>Methylprednisolone Hemisuccinate</mesh_term>
	<mesh_term>Prednisolone hemisuccinate</mesh_term>
	<mesh_term>Prednisolone phosphate</mesh_term>
	<criteria>1 . Willing able give inform consent prior study specific procedure perform . In individual hepatic encephalopathy ( HE ) may impair decisionmaking , consent obtain per hospital procedure ( eg , Legally Authorized Representative ) 2 . Clinical diagnosis severe AH 3 . Maddrey 's DF ≥ 32 screen Key 1 . Pregnant lactating female ; 2 . Other cause liver disease include chronic hepatitis B ( hepatitis B surface antigen [ HBsAg ] positive ) , chronic hepatitis C ( HCV RNA positive ) , acetaminophen hepatotoxicity , biliary obstruction , autoimmune liver disease ; 3 . Serum AST &gt; 400 U/L ALT &gt; 300 U/L ; 4 . MELD &gt; 30 screening ; 5 . Maddrey 's DF &gt; 60 screening ; 6 . Grade 4 Hepatic Encephalopathy ( HE ) West Haven criterion ; 7 . Concomitant previous history hepatocellular carcinoma ; 8 . History liver transplantation ; 9 . HIV Ab positive ; 10 . Clinical suspicion pneumonia ; 11 . Uncontrolled sepsis ; 12 . Uncontrolled gastrointestinal ( GI ) bleed control GI bleed within 7 day screen associated shock require transfusion 3 unit blood ; 13 . Type 1 hepatorenal syndrome ( HRS ) renal failure define serum creatinine &gt; 221 μmol/L ( &gt; 2.5 mg/dL ) requirement renal replacement therapy ; 14 . Individuals dependent inotropic ( eg , epinephrine norepinephrine ) ventilatory support ( ie , endotracheal intubation positivepressure ventilation ) ; 15 . Portal vein thrombosis ; 16 . Acute pancreatitis ; 17 . Cessation alcohol consumption 2 month Baseline/ Day 1 NOTE : Other protocol define Inclusion/ Exclusion criterion may apply .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>